Buy or sell MacuLogix stock pre IPO via an EquityZen fund
Detecting and tracking age-related macular degeneration
About MacuLogix Stock
MacuLogix aims to detect early and track age-related macular degeneration (AMD). MacuLogix’ AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD.
Co-founder and Chief Scientific Officer
Gregory R. Jackson